Trial Profile
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Dostarlimab (Primary) ; Niraparib (Primary)
- Indications Adenocarcinoma; Carcinoma; Clear cell sarcoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms FIRST
- Sponsors GlaxoSmithKline; GSK; TESARO
- 11 Mar 2024 According to an AnaptysBio media release, GSK anticipates top-line data in H1 2024 from this FIRST Phase 3 trial for platinum-based therapy with dostarlimab and niraparib versus platinum-based therapy as first-line treatment of Stage III or IV nonmucinous epithelial ovarian cancer.
- 31 Jul 2023 Planned primary completion date changed from 21 Jul 2023 to 29 Mar 2024.
- 28 May 2021 Planned primary completion date changed from 20 Jan 2023 to 21 Jul 2023.